GU Cancers 2023 | Clinical trials investigating overcoming resistance to ICIs for RCC
Tian Zhang, MD, MHS, UT Southwestern Medical Center, Dallas, TX, discusses ongoing clinical trials investigating how to overcome resistance to checkpoint inhibitors in patients with advanced renal cell carcinoma (RCC). Dr Zhang talks on the TiNivo-2 trial (NCT04987203) which is comparing tivozanib plus nivolumab to tivozanib alone, as well as the CONTACT-03 trial (NCT04338269), which is comparing atezolizumab plus cabozantinib to cabozantinib alone. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, lot of thoughts around once we have multiple agents approved in the first line setting for metastatic disease, how are these patients progressing? What are they developing in terms of resistance mechanisms and how can we target those effectively? For the moment, we have extrapolated from active therapies in the frontline setting to the refractory setting. And so, we do have combinations like lenvatinib and pembrolizumab, which was studied in a phase two trial with activity in the post IO treated patient population...
So, lot of thoughts around once we have multiple agents approved in the first line setting for metastatic disease, how are these patients progressing? What are they developing in terms of resistance mechanisms and how can we target those effectively? For the moment, we have extrapolated from active therapies in the frontline setting to the refractory setting. And so, we do have combinations like lenvatinib and pembrolizumab, which was studied in a phase two trial with activity in the post IO treated patient population. In addition, there are multiple ongoing trials. The TiNivo-2 trial is testing the combination of tivozanib with nivolumab. And the CONTACT-03 trial is testing the combination of cabozantinib with atezolizumab. And of the two, CONTACT-03 is finished accruing and we’re looking forward to results later this year. I think in particular, we should be thinking about how we target mechanisms of resistance and really studying these patients more in detail so that we can find ways to overcome resistance to checkpoint inhibitors.
Read more...
